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Abstract:  46	
 47	
Venous valve (VV) failure causes chronic venous insufficiency, but the molecular 48	
regulation of valve development is poorly understood. A primary lymphatic 49	
anomaly, caused by mutations in the receptor tyrosine kinase EPHB4, was recently 50	
described, with these patients also presenting with venous insufficiency. Whether the 51	
venous anomalies are the result of an effect on VVs is not known. VV formation 52	
requires complex ‘organization’ of valve-forming endothelial cells, including their 53	
reorientation perpendicular to the direction of blood flow. Using quantitative 54	
ultrasound we identified substantial VV aplasia and deep venous reflux in patients 55	
with mutations in EPHB4. We used a GFP reporter, in mice, to study expression of its 56	
ligand, ephrinB2, and analysed developmental phenotypes following conditional 57	
deletion of floxed Ephb4 and Efnb2 alleles. EphB4 and ephrinB2 expression patterns 58	
were dynamically regulated around organizing valve-forming cells. Efnb2 deletion 59	
disrupted the normal endothelial expression patterns of the gap junction proteins 60	
connexin37 and connexin43 (both required for normal valve development) around 61	
reorientating valve-forming cells, and produced deficient valve-forming cell 62	
elongation, reorientation, polarity, and proliferation. Ephb4 was also required for 63	
valve-forming cell organization, and subsequent growth of the valve leaflets. These 64	
results uncover a potentially novel cause of primary human VV aplasia. 65	
 66	
 67	
 68	
Keywords: Venous valve / reflux / primary aplasia / chronic venous 69	
insufficiency  70	
  71	
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Introduction 72	
 73	
Unidirectional blood flow requires functional venous valves (VVs) which are widely 74	
distributed throughout human veins and venules, predominantly in vessels less than 75	
100µm in diameter.(1) Lower limb VVs are typically bicuspid and situated just 76	
upstream of the confluence with a tributary.(1, 2) Failure of these valves is the central 77	
feature of the venous reflux that is seen in up to 40% of adults,(3, 4) while congenital 78	
venous valve aplasia has also been identified.(5-8) In the lower limbs, venous reflux 79	
causes chronic venous hypertension, leading to pain, oedema, hyperpigmentation, 80	
skin damage, and chronic intractable ulceration.(3, 9, 10) Our understanding of the 81	
molecular mechanisms of VV embryological development, maintenance after 82	
formation, and failure in disease is limited, and there are few therapeutic options to 83	
treat VV dysfunction.(3, 11-16) Elucidating these mechanisms and understanding 84	
how their dysfunction may lead to VV failure could facilitate the development of novel 85	
therapies.  86	
 87	
Clinical studies have suggested a link between venous reflux and some primary 88	
lymphedemas, and we have previously shown striking human VV disease in patients 89	
with primary lymphedema caused by mutations in FOXC2 (MIM 602402) and GJC2 90	
(MIM 608803).(11, 17-20) Other human genetics studies have shown that mutations 91	
in the gene encoding the tyrosine kinase receptor EPHB4 (EPHB4, MIM 618196), 92	
cause capillary malformation-arteriovenous malformation syndrome (CM-AVM2, 93	
including hereditary haemorrhagic telangiectasia and vein of Galen malformations, 94	
cutaneous malformations and arteriovenous malformations) and a primary lymphatic 95	
anomaly which includes clinical features such as central conduction lymphatic 96	
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anomaly, non-immune fetal hydrops, and atrial septal defects. (21-28). Patients with 97	
the primary lymphatic anomaly were also reported to present with varicose veins and 98	
early onset venous stasis.(21, 25, 28) In mice, early embryonic deletion of Ephb4 in 99	
lymphatic endothelia leads to subcutaneous oedema and abnormal dermal and 100	
mesenteric lymphatic vasculature, whereas deletion in adult blood endothelia results 101	
in coronary abnormalities including capillary microhaemorrhages.(21, 29)  102	
 103	
The Eph’s are the largest family of mammalian receptor tyrosine kinases and bind to 104	
ephrins, their trans-cellular ligands.(30, 31) Cell-cell signaling may occur in either 105	
direction, resulting in cell and context-specific effects, and is involved in regulating 106	
many developmental processes including cell sorting and boundary formation.(32-34) 107	
In the cardiovascular system ephrinB2 is widely accepted as an arterial-specific 108	
marker, whereas EphB4 is used as a marker of venous endothelia.(35-37) EphrinB2-109	
EphB4 signaling is essential for developmental angiogenesis, and global knockout of 110	
Ephb4 is phenotypically similar to knockout of Efnb2, with both resulting in vascular 111	
remodeling defects and embryonic lethality.(35, 38-40) Constitutive overexpression 112	
of ephrinB2 leads to defects including abnormal intersomitic vessel patterning, aortic 113	
dissection and aneurysm formation, and early neonatal lethality due to aortic 114	
rupture.(41) 115	
  116	
Signaling between ephrinB2 and EphB4 is required for lymphatic valve (LV) 117	
development and maintenance, and for formation of valves at lymphovenous 118	
junctions at the base of the neck.(12, 21, 42) LV cells fail to take on normal 119	
morphology in Efnb2ΔV/ΔV mice (lacking the C-terminal PDZ interaction site), and it 120	
was suggested that ephrinB2-EphB4 signaling is required to guide endothelial cell 121	
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(EC) migration and elongation during LV morphogenesis.(42) Blocking the forward 122	
signaling activity of EphB4 results in failure of LV formation.(43, 44) Defects in 123	
cardiac valve (CV) development leading to early perinatal death are found in 124	
Efnb2βgal/βgal mice, in which the cytoplasmic tail of ephrinB2 is replaced with βgal.(45) 125	
In both LV and CV, the morphological effects of loss (or inhibition) of ephrinB2-126	
EphB4 signaling on Prox1hi valve-forming cells (VFCs) remain unclear. Ephrin-Eph 127	
interactions result in rapid changes in cellular direction and motility, leading to 128	
boundary formation within initially mixed populations of cells (for example, in 129	
mesenchymal cells), and can inhibit communication via gap junctions across these 130	
boundaries.(31, 32, 46) In vitro, ephrinB2-EphB4 signaling controls EC repulsion and 131	
segregation, leading to clustering of EphB4- or ephrinB2-expressing cells, akin to in 132	
vivo boundary formation, but to the best of our knowledge this behaviour has not 133	
been observed in ECs in vivo.(47) 134	
 135	
We previously showed that ephrinB2 is required for postnatal VV leaflet development 136	
and maintenance, but the expression of ephrinB2 and EphB4, and any roles in the 137	
early organization of VFCs, have not been examined.(11, 12) In this study, we show 138	
that mutations in EPHB4 cause striking human VV disease, with an almost complete 139	
loss of VVs seen in some patients. Given the known roles for ephrin-Eph interactions 140	
in boundary formation in other tissues, we hypothesised that ephrin-Eph interactions 141	
could regulate early organizational events in VV formation. We have therefore 142	
focused on their respective roles in the regulation of the complex series of events 143	
during early valve formation in mice, which includes the organization of a set of 144	
Prox1hi VFCs to form a ring of cells within the three-dimensional lumen of the vessel 145	
(stage 1 of development).(11, 12) At P0 this structure is found predominantly on the 146	
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anterior vein wall, and then extends posteriorly.(11) Using a GFP reporter we 147	
identified Efnb2 expression within veins at the site of VV formation, and that the 148	
organization of VFCs occurs at a striking boundary between venous ECs that 149	
express ephrinB2 and those that do not. A conditional loss-of-function genetic 150	
approach has enabled us to show that both ephrinB2 and EphB4 are required for 151	
these early organizational events and that EphB4 is required for postnatal VV 152	
development.  153	
 154	
  155	
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Results 156	
Patients with mutations in EPHB4 have fewer VVs and show deep venous 157	
reflux 158	
 159	
Pathogenic mutations in EPHB4 were recently described in two families with primary 160	
lymphatic related fetal hydrops (LRFH), with autosomal dominant inheritance.(21) 161	
Adults in both families had a notably early onset of lower limb venous disease. We 162	
therefore characterised the numbers of valves per vein in these patients (N=5) and 163	
an unaffected relative using ultrasonography, and compared these results to a 164	
control population (N=12, Supplementary Table 1). VVs were readily detected in the 165	
unaffected relative and other controls, but fewer VVs were detected in patients 166	
carrying a heterozygous mutation in EPHB4, including three patients with a mosaic 167	
mutation in EPHB4 (fold change 0.2 ±SD 0.29 for mosaic carriers, and 0.17±0.36 for 168	
constitutive carriers, P=1.7x10-11, ANOVA: F=30.3, 2df, Figure 1A,B, and 169	
Supplementary Figure 1). 92 veins were analysed in 13 controls, and 40 veins were 170	
analysed in 5 mosaic or constitutive EPHB4 mutation carriers. Given the substantial 171	
loss of VVs in those with constitutive EPHB4 mutations, too few VVs were available 172	
for detailed analysis of leaflet length in constitutive mutation carriers, but those VVs 173	
that were identified were not significantly shorter than controls (Supplementary 174	
Figure 1, fold change 1.15±0.63 for mosaic carriers, and 0.67±0.48 for constitutive 175	
carriers, P= not significant).  Groups were matched for age and sex (P= not 176	
significant). Those carrying an EPHB4 mutation had a mean popliteal reflux duration 177	
of 1.37s, above the accepted diagnostic threshold of 1s for severe deep venous 178	
reflux. Both patients with constitutive EPHB4 mutations exhibited a mean popliteal 179	
vein reflux duration ≥1s (Figure 1C,D, Supplementary Figure 1). 180	
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 181	
EphB4 is expressed at E18 and P0 and is required for normal VFC organization  182	
EphB4 is the main ephrinB2 receptor in the vasculature, and these proteins often 183	
exhibit a complementary expression pattern during tissue segmentation.(13, 35) Our 184	
analysis initially focused on embryonic day 18 (E18) and postnatal day 0 (P0). We 185	
localised EphB4 expression in the region of the developing valve in Efnb2GFP mice, 186	
and then examined whether EphB4 is required for organization of VFCs at P0.  187	
 188	
At E18, when VFCs are in the process of organizing themselves at the site of 189	
developing valves, EphB4 expression appeared to be stronger immediately upstream 190	
of areas showing VFC organization, and adjacent to VFCs with high Efnb2 191	
expression (Figure 2A, Supplementary Figure 2C). Quantification of Efnb2GFP signal 192	
and EphB4 immunosignal across these organizing areas (yellow box in Figure 2A) 193	
confirmed relatively complementary expression with significantly higher EphB4 194	
upstream and higher Efnb2GFP downstream of the VFCs (Figure 2B). Conversely, 195	
VFCs nearer the superior or inferior edges of the vessel already coexpressed 196	
Efnb2GFP and EphB4 (arrowheads in Figure 2A).  197	
 198	
By P0, VFCs consistently reorientate and elongate to form a line of cells across the 199	
anterior femoral vein wall, and partly extend across the posterior wall, defined as 200	
stage 1 of VV development (schematic in Figure 2A). Prior to this, development is 201	
described as stage 0. We had thought that EphB4 expression would be 202	
complementary to Efnb2 expression at P0, but EphB4 was immunolocalised variably 203	
throughout the valve region, with stronger expression within clusters of VFCs at the 204	
superior and inferior regions of the valve (Figure 2C, arrowheads), where we 205	
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previously identified multiple proliferating VFCs.(11) Co-expression of Ephb4 and 206	
Efnb2 was confirmed in Efnb2GFP mice (Figure 2D and Supplementary Figure 2B). 207	
Deletion of Ephb4 at E15 resulted in disorganized VFCs at P0 (Figure 3A) albeit 208	
some VVs developed normally to stage 1 (Figure 3B). 209	
 210	
Ephb4 is required for leaflet development to P6 211	
 212	
We next localised the expression of EphB4 in VV leaflets at P6 and in adult mice. We 213	
then examined whether EphB4 is required for maturation of the valve leaflets up to 214	
P6.  215	
 216	
EphB4 continued to be expressed in the endothelia of veins and VV leaflets at P6 217	
and in adults (Figure 3C, left panel). Expression was strongest on the lumen surface 218	
of the valve leaflet, including cells at the free edge of valve leaflet (Figure 3C, right 219	
panel). This expression is complementary to the previously identified lack of 220	
expression of Efnb2 in these free edge cells.(12) This could contribute to 221	
maintenance of their phenotype, which is clearly different to the rounded morphology 222	
of endothelia lining the sinus or lumen leaflet surfaces.(12)    223	
 224	
At P6 VVs are normally at stages 3 or 4 (schematic in Figure 3), which were defined, 225	
as previously, by the presence of one or two commissures.(11) Deletion of Ephb4 at 226	
P0 led to a complete failure of valve leaflet formation by P6, with only a few Prox1- or 227	
Foxc2-expressing cells remaining (Figure 3D,E). This phenotype (Ephb4 deletion at 228	
P0, analysed at P6) was more consistent and severe than deletion at E15, analysed 229	
at P0 (Figure 3A).  230	
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 231	
Similarly to other gene-deletion studies resulting in loss of VFCs by P6, there was an 232	
associated failure to establish a local reduction in the density of smooth muscle cells 233	
(SMCs) around the valve (Figure 3D).(11) 234	
 235	
VFC organization occurs at a developing boundary between ECs expressing 236	
and not expressing Efnb2 237	
 238	
To visualise the Efnb2 expression pattern during VFC organization we visualised the 239	
site of VV formation in the proximal femoral vein using confocal microscopy of 240	
wholemount samples from Efnb2GFP reporter mice (Figure 4A). Efnb2GFP signal was 241	
strong in femoral artery ECs (Figure 4A, FA), and generally absent or at very low 242	
levels in venous endothelia in all samples analysed, similar to previously reported 243	
findings.(36, 37) Expression of Efnb2 by venous smooth muscle α-actin-expressing 244	
mural cells was not detected (data not shown). Global heterozygous knockout of 245	
Efnb2 (in the Efnb2GFP reporter) did not prevent development of stage 1 VVs by P0 246	
(P = NS vs wildtype littermates, N=32 Efnb2GFP/wt VVs analysed). At E18 the 247	
patterning of Prox1hi VFCs within the valve-forming region was more variable than at 248	
P0, with areas of Prox1hi cells (e.g. the superior but not inferior area) showing 249	
organization (i.e. reorientation and elongation of cells, Figure 4A, upper panel vs 250	
lower panel). The organizing VFCs, and endothelia just downstream of organizing 251	
VFCs, expressed Efnb2 (Figure 4A, green box), whilst areas without VFC 252	
organization did not develop a boundary in ephrinB2 expression (Figure 4B, blue 253	
box). Quantification of the Efnb2GFP signal at E18 confirmed a boundary in 254	
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expression of Efnb2 in regions of organized cells, but not in adjacent non-organized 255	
regions (Figure 4B).  256	
 257	
At P0 Efnb2 was consistently expressed (and more strongly than at E18) by the line 258	
of Prox1hi VFCs and in cells downstream, but not upstream, of the VFCs (Figure 4A, 259	
lower panel). Quantification confirmed the boundary in Efnb2GFP signal, with a peak 260	
in Efnb2 expression coinciding with Prox1hi VFCs (Figure 4C). Whilst at E18 the 261	
downstream Efnb2GFP signal was marginally higher than the upstream signal (Figure 262	
4A,B), by P0 this difference was more marked (Figure 4A,C). These results suggest 263	
that the Efnb2 expression boundary is formed concomitantly with the organization of 264	
Prox1hi VFCs, and suggest that an Eph-ephrin interaction within venous endothelia 265	
might participate in the regulation of VFC organization.  266	
 267	
Analysis of this valve-forming region at P0 in wildtype mice by transmission electron 268	
microscopy (TEM) demonstrated that development of the core of the valve leaflet is 269	
more advanced than previously characterised, with the presence of interstitial cells 270	
within the leaflet, which is already protruding from the vessel wall (Figure 4D, upper 271	
panel).(11) VFCs at the leading edge of the protruding leaflet were partly detached 272	
from the underlying basement membrane, consistent with their progressive 273	
reorientation and migration (Figure 4D, upper panel, arrowheads), as has previously 274	
been identified in developing LV.(48) TEM analysis at P6 and in adult mice confirmed 275	
the presence of interstitial cells in murine VV (Figure 4D, middle and lower panels, 276	
Supplementary Figure 3A-C), consistent with their known presence in, for example, 277	
rabbit VV.(2) The presence of interstitial cells in human VV was confirmed by TEM 278	
and histology (Supplementary Figure 3D,E). Connexin43 and Connexin47, proteins 279	
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implicated in human VV disease,(11) were immunolocalised to human VV interstitial 280	
cells (Supplementary Figure 3F).  281	
Efnb2 is required for normal VFC organization 282	
Having established the expression pattern of Efnb2 during VFC organization, we then 283	
examined whether Efnb2 is required for the organization of VFCs at P0. We 284	
performed conditional gene deletion using floxed Efnb2 alleles and Prox1CreERT2, 285	
and quantified each valve according to developmental stage and also quantified the 286	
elongation and reorientation of Prox1hi cells (as previously described).(11, 12, 48) 287	
Heterozygous deletion at E15 did not significantly affect VV development to stage 1 288	
(Figure 5A middle panel, and B). There was, however, a small but significant 289	
reduction in VFC nuclear elongation (Figure 5C,D), but no difference in their 290	
reorientation (Figure 5E,F). Homozygous deletion of Efnb2 resulted in disorganized 291	
VFCs that failed to reach stage 1 of development at P0, with a similar pattern of 292	
disorganization to that seen with deletion of Ephb4 (P<0.001, Figure 5A lower panel, 293	
and B). Prox1hi cells were present but appeared to be distributed across a wider 294	
upstream-downstream region of the vessel, and exhibited markedly reduced 295	
elongation (Figure 5C,D, P<0.00005) and reorientation (P<0.005, Figure 5E-F). 296	
These findings demonstrate that endothelial Efnb2 is required for the normal 297	
organized patterning of VFCs at P0. 298	
 299	
These results, together with those we described for Ephb4, show that the expression 300	
of EphB4 and Efnb2 is dynamic during VV organization, and complementary 301	
expression (Efnb2 higher downstream, EphB4 higher upstream) occurs during the 302	
process of organization at E18, but by P0 VFCs express both Efnb2 and EphB4.  303	
 304	
	 12	
 305	
Efnb2 is required for projection of VFCs into the vessel lumen, normal 306	
expression of integrin-α9, and normal polarity 307	
 308	
We prepared longitudinal semi-thin sections in the XZ-plane of the wholemount 309	
preparations, to more clearly examine projection of VFCs into the vessel lumen. 310	
Compared with littermate controls VFCs failed to project into the vessel lumen in 311	
homozygous Efnb2-deleted cells (Figure 6A,B). We hypothesised that failure to 312	
correctly express integrin-α9 could be a mechanism underlying the failure of VFCs to 313	
organize and project into the lumen in Efnb2-deleted mice, as integrin-α9 is required 314	
in valve formation for extracellular matrix remodeling, and for VV leaflet growth and 315	
maintenance.(11, 12, 49) At P0 integrin-α9 expression was largely localised to the 316	
line of VFCs on the anterior vein wall (Figure 6C, upper panel). After Efnb2 deletion, 317	
the integrin-α9 expression pattern followed the abnormal, broader distribution of the 318	
Prox1hi cells, and appeared haphazard (Figure 6C), likely precluding normal matrix 319	
remodeling. 320	
 321	
Because VFCs appeared in a broader region after Efnb2 deletion, we hypothesised 322	
that without guidance from ephrin-Eph interactions at E18 these cells would be 323	
disorientated at P0. In LV formation, lymphatic ECs elongate and migrate centrally 324	
from the edges of the vessel (48, 50) and in migratory ECs, the Golgi apparatus is 325	
positioned apically of the nucleus.(51) We therefore analysed VFC alignment by co-326	
staining for a Golgi marker, and examined the alignment of cells with the forming VV 327	
structure (Figure 6D, upper panel). In littermate controls at P0, cells were consistently 328	
	 13	
aligned across the vessel anterior wall, whilst in all samples with homozygous Efnb2 329	
deletion there was a disrupted pattern (Figure 6D, lower panel). 330	
Gap junction intercellular communication and proliferation 331	
Expression of ephrinB’s may regulate cell behaviour by modulating connexin 332	
communication domains, including via Connexin43 (Cx43).(32, 46) Cx43 and 333	
Connexin37 (Cx37) have highly regulated expression patterns around VFCs at P0, 334	
and both are required for venous, lymphatic, and lymphovenous valve formation.(11, 335	
13, 14, 52-54) Large gap junction plaques containing Cx37 are normally expressed 336	
by Prox1hi VFCs at P0, whilst Cx43 is primarily expressed in a region just upstream 337	
of the organized VFCs at P0. Homozygous deletion of Cx43 (using Prox1CreERT2), or 338	
homozygous knockout of Cx37, results in a failure of organization of VFCs at P0, 339	
which is reminiscent of the phenotype seen with homozygous deletion of Efnb2.(11, 340	
13, 14) This failure of organization at P0 is followed by complete loss of valve 341	
structure.(13) We therefore examined the expression patterns of Cx37 and Cx43 342	
relative to Efnb2 expression in the Efnb2GFP reporter mice, and after homozygous 343	
deletion of Efnb2. The normally highly restricted expression patterns of Cx37 and 344	
Cx43 were disrupted at P0 following homozygous Efnb2 deletion (Figure 7A,B). In 345	
the Efnb2GFP reporter, Cx37 localisation indicated gap junction plaque formation 346	
around Efnb2-expressing VFCs (Figure 7A, white arrowheads in upper panel), whilst 347	
after Efnb2 deletion, no plaque formation was identified (or possibly plaques were 348	
very much smaller), and Cx37 expression appeared more widespread in the region of 349	
the VFCs (Figure 7B).  350	
 351	
In previous genetic loss-of-function experiments (including knockout of Cx37), 352	
disruption of VFC organization was associated with a reduction in VFC 353	
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proliferation,(11) and so we next examined whether deletion of Efnb2 altered VFC 354	
proliferation or apoptosis. As previously, Ki67-positive proliferating VFCs appeared 355	
more abundant in the superior & inferior regions of the valve at P0.(11) A reduction in 356	
the proportion of proliferating VFCs was seen following Efnb2 deletion (P<0.001, 357	
Figure 7C,D), but no effect on apoptosis (as detected by Caspase-3 expression) was 358	
observed (data not shown).  359	
  360	
	 15	
Discussion 361	
 362	
We have identified human venous valve failure and deep venous reflux caused by 363	
mutations in EPHB4. This phenotype was more severe (i.e. a greater loss of valves) 364	
than that previously identified in patients with mutations in FOXC2 or GJC2 (a fold 365	
change vs controls of 0.2 ±SD 0.29 (mosaic EPHB4) or 0.17 ±0.36 (constitutive	366	
heterozygous EPHB4) for the reduction in mean VVs per vein).(11) Almost all of 367	
these patients did not have clinical evidence of chronic lower limb primary 368	
lymphedema. Some presented with non-immune foetal hydrops, which was of 369	
lymphatic origin, but it had resolved soon after birth. Following that, their most 370	
obvious clinical sign of disease was early onset prominent or varicose veins, and 371	
venous insufficiency.(21) We now know that this is venous valvular aplasia, and 372	
therefore mutations in EPHB4 should be considered as a cause of primary venous 373	
valvular aplasia.(5-8, 21, 55) Dysfunction of the deep venous valves increases the 374	
rate of progression of chronic venous insufficiency, with a higher rate of chronic 375	
venous ulcer formation. The management of deep venous reflux is extremely 376	
challenging, as currently there are no reliably effective therapies beyond invasive 377	
surgical construction of neovalves.(3)	378	
 379	
Heterozygous mutations in EPHB4 are reported to cause CM-AVM2, vein of Galen 380	
aneurysmal malformation, Lymphatic Related Foetal Hydrops (LRFH), and central 381	
conducting lymphatic anomaly (CCLA), but the mechanism(s) underlying these 382	
different presentations remain unclear.(21, 22, 25, 26, 28) The clinical descriptions of 383	
patients with a lymphatic phenotype such as LRFH and CCLA also include clear 384	
features of venous disease such as varicose veins, venous hypertension or venous 385	
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reflux. Similar to the cases presented, it seems likely that the patients reported by Li 386	
et al may also be affected by VV aplasia and deep venous reflux (considering their 387	
increased lower limb pigmentation and venous stasis).(25) The early age at onset of 388	
clinical signs of venous insufficiency (for example varicose veins, hemosiderin 389	
deposition) in affected individuals, and the near absence of VVs in the scanned veins 390	
of affected children observed here, is consistent with a failure of VV formation, rather 391	
than early degeneration. These features are not described for CM-AVM2, or vein of 392	
Galen aneurysmal malformation, and it is unclear whether the mutations causing 393	
these syndromes will also cause VV defects.(22, 26) EphrinB2 is required for normal 394	
cardiac valve (CV) formation in mice, but no CV defects were noted on 395	
echocardiography in the patients reported here, or those reported elsewhere.(21, 25, 396	
28) It remains unclear how, in the settings of developmental blood vessel formation 397	
and in the adult capillary bed, ephrinB2-EphB4 interaction leads to specification and 398	
subsequent maintenance of arterial and venous endothelia, yet both are expressed in 399	
mature veins to regulate the formation of valves.(12, 22, 23, 38, 41) Further work is 400	
needed to delineate the context and maturation-dependent regulation of these 401	
endothelia. 402	
 403	
Previous in-vitro analysis of the EPHB4 mutations studied here (p.Arg739Glu and 404	
p.Ile782Ser) demonstrated that they exhibit greatly reduced kinase activity, but do 405	
not exert a dominant negative effect on the expression of wildtype EPHB4 406	
protein.(21) Any effect on wildtype EPHB4 activity is unknown. The ratio of ephrinB2 407	
to EphB4 expression is disturbed at both mRNA and protein level in ECs cultured 408	
from patient arterio-venous malformations, with greatly reduced EphB4 expression 409	
compared to a control cell line.(56) The mutant EPHB4 protein implicated in CM-410	
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AVM2 becomes trapped in vesicles (22, 28), whilst that implicated in LRFH is 411	
presented on the cell membrane (28), but the exact signalling implications of these 412	
findings are yet to be elucidated. The requirement for ephrin-Eph signalling at 413	
multiple stages of VV development and maintenance complicates any attempt to 414	
develop molecular therapy aiming to directly restore valve function. It is possible that 415	
pharmacological stimulation or inhibition of the pathway downstream of EPHB4 might 416	
be helpful to overcome the resulting aberrant signalling.(22, 25)  417	
 418	
The extent of overlap of the genetic causes of venous valve failure and varicose 419	
veins is unclear since regulation of VVs is understudied, but some important 420	
indications of similarity have already emerged, including the identification of PPP3R1 421	
and PIEZO1 in genome wide association studies of varicose veins, and in mice as 422	
critical regulators of VV development.(11, 57, 58) Delineating the roles of the various 423	
genes implicated in VV pathogenesis is important and may lead to novel therapies, 424	
which could be targeted towards patients at risk of deterioration to chronic 425	
ulceration.(59)  426	
 427	
In this study we have identified a striking ‘boundary’ in the endothelial expression of 428	
Efnb2 at the site of developing VVs (meaning a demarcation between ephrinB2lo 429	
upstream cells and ephrinB2hi VFCs and cells immediately downstream), and that 430	
both ephrinB2 and EphB4 are required for normal organization of VFCs at this critical 431	
stage of development in mice. Since ephrinB2 remains the only known ligand for 432	
EphB4, this leads us to speculate that an ephrinB2-EphB4 interaction within venous 433	
endothelia regulates VV formation. We also show that EphB4 is required for VV 434	
maturation. At E18, in areas where VFCs appeared to be in the process of 435	
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reorientating to become transversely aligned, EphB4 expression was stronger just 436	
upstream of the ephrinB2-expressing VFCs. We speculate that at this time point, 437	
EphB4hi regions upstream from VFCs may be acting to repel ephrinB2hi VFCs, 438	
guiding them to reorientate to lie transversely across the vessel to form a line across 439	
the anterior of the lumen. We were unable to localise ephrinB2 because of a lack of 440	
specific antibodies, and this inability to colocalise EphB4 and ephrinB2 is a limitation 441	
of our study. In wildtype littermates VFC polarity was aligned with the boundary and 442	
developing ring of VFCs, whilst after Efnb2 deletion VFC polarity was disorganized 443	
and cells were spread over a wider upstream-downstream region. These results are 444	
consistent with previous in-vitro findings, showing that ephrinB2-EphB4 interaction 445	
leads to separation and clustering of initially mixed populations of EphB4- and 446	
ephrinB2-expressing ECs.(47) In-vitro, treatment with ephrinB2-Fc stimulates 447	
migration of HUVECS, and it is possible that ephrinB2 promotes the migration of 448	
VFCs.(60) 449	
 450	
It remains unknown how Efnb2 expression within veins is regulated. We have shown 451	
that the Efnb2 boundary forms as the VFCs organize, and it may be regulated by the 452	
VFCs themselves as they organize. Notably, BMP9 controls lymphatic remodeling 453	
and LV formation, and also induces Efnb2 expression in lymphatic and blood 454	
endothelia in vitro, but it is not known whether there is a VV phenotype in Bmp9-/- 455	
mice.(61, 62) The extent to which there is proliferation of VFCs between E18 and P0, 456	
or whether there is de-novo differentiation of new Prox1hi cells from surrounding 457	
endothelium, remains unclear. 458	
 459	
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Normal blood flow is required for postnatal VV maturation (11) and Efnb2-dependent 460	
protrusion of cells into the lumen at P0 could expose VFCs to higher fluid shear 461	
forces, particularly as the vessel lumen becomes more acutely narrowed (e.g. at 462	
stage 2 of VV development).(12) Shear-regulated signaling might co-ordinate 463	
subsequent events in VV formation, for example commissure formation. In embryonic 464	
stem cell derived ECs in vitro, Efnb2 is upregulated by shear stress, which may 465	
contribute to the stimulation of VV leaflet growth post-natally.(12, 63) This notion is 466	
consistent with the role of the oscillatory shear stress/Gata2/Foxc2 axis in LV 467	
endothelial differentiation, and the potential role of wall shear stress gradients in 468	
demarcating the locations of valve formation upstream of tributaries.(64-66) Deletion 469	
of the mechanosensory ion channel Piezo1 results in defective VVs at P3, again 470	
consistent with a role for fluid shear in patterning VV (in addition to LV) formation.(57, 471	
67) 472	
 473	
Signaling downstream of ephrin-Eph interactions can, for example, inhibit gap 474	
junction formation at the boundary between two cell populations, likely by cell 475	
repulsion preventing stable contacts between cells.(32) It seems likely that cell-cell 476	
repulsion between ephrinB2hi VFCs and EphB4hi;ephrinB2lo upstream cells at E18 477	
patterns the migration of VFCs. It is unknown whether gap-junction signalling is 478	
important in this process, but loss of either Cx37 or Cx43 in mice leads to a similar 479	
phenotype with failure of VFC organization.(11) Homozygous Efnb2 deletion 480	
disrupted the normally highly restricted expression patterns of Cx37 and Cx43 at P0, 481	
suggesting that gap junctional communication is disrupted. Gap junction plaque size 482	
varies depending on how many channels are clustered in the plaque. It is possible 483	
that plaques were present but much smaller, although this would also be expected to 484	
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reduce cell-cell communication.(68) We were unfortunately unable to develop 485	
experiments to demonstrate gap junctional VFC cell-cell communication in vivo, or 486	
confirm how this may be disrupted after deletion of Ephb4 or Efnb2.  487	
 488	
Mutations in EFNB1 cause craniofrontonasal syndrome, whilst mice heterozygous for 489	
Efnb1 display skull defects that are thought to be mediated by inhibition of normal 490	
gap-junctional communication via Cx43 at ectopic ephrin-Eph boundaries. EphrinB1 491	
directly interacts with Cx43 and regulates its cellular distribution, and disruption of 492	
gap junction plaques was seen in Efnb1+/- mice.(46) Whilst deletion of Efnb2 resulted 493	
in loss of large Cx37 plaques in VFCs, any direct interaction between ephrinB2 and 494	
Cx37 remains to be determined. Although not directly demonstrated in our 495	
experiments, it is reasonable to assume that following Efnb2 deletion, as the Prox1hi 496	
VFCs are further apart and are physically separated, there will be less 497	
communication between these cells via gap junctions (e.g. incorporating Cx37). 498	
EphrinB2 organizes VFC positioning and therefore facilitates the formation of 499	
functional gap junctions between adjacent VFCs. It is plausible, therefore, that 500	
disruption of connexin expression patterning and gap junctional communication may 501	
be part of the mechanism that underlies the phenotype seen following Efnb2 502	
deletion.(46) 503	
 504	
In wildtype mice at P0 Cx43 was expressed upstream of the developing VV and was 505	
not clearly expressed by the Prox1hi VFCs that express ephrinB2.(11) Cx43 is clearly 506	
expressed by cells that also express EphB4. With deletion of Efnb2, Cx43 expression 507	
appeared more dispersed throughout the femoral vein, suggesting ephrinB2 is 508	
required for the restriction of the Cx43 expression domain. In cardiomyocytes, EphB4 509	
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physically associates with Cx43, and EphB activation inhibited cardiomyocyte gap 510	
junctional electrical coupling.(69) It is possible that in upstream endothelia, signaling 511	
through EphB4 could inhibit gap junction communication via Cx43.  512	
 513	
It is unclear why the VV phenotype following Ephb4 deletion was slightly weaker than 514	
that in Efnb2 deleted mice. EphrinB2 is more promiscuous, binding to EphB4, EphB3 515	
and EphB2, while EphB4 exclusively interacts with ephrinB2.(38, 70) Isolated 516	
knockout of either Ephb2 or Ephb3 does not induce any cardiovascular phenotype, 517	
but a third of double knockouts have severely defective angiogenesis that resembles 518	
much of the phenotype of Efnb2-/- mice.(38) EphB3 expression has been reported in 519	
veins (while EphB2 is expressed in nonvascular mesenchymal cells), but we could 520	
not detect specific signals for EphB2 or EphB3 in veins by immunohistology (data not 521	
shown). EphrinB2 regulates cell morphology and motility independently of binding its 522	
receptors in vitro, which could partly explain the stronger phenotype seen with Efnb2 523	
deletion.(71) In sprouting angiogenesis, ephrinB2 is required for endocytosis and 524	
signalling of other important regulators of EC function including Vegfr2 and Vegfr3 525	
(which are expressed in developing VVs), and could play similar roles in VFC 526	
organization.(12, 39, 40)  The slight difference in the phenotypes following deletion 527	
of Efnb2 and Ephb4 could be caused by differences in their protein stability, which 528	
we were unable to investigate, in part because of the lack of specific antibodies 529	
raised against ephrinB2. We could not confirm reduced Ephb4 or Efnb2 mRNA levels 530	
following conditional gene deletion, due to our inability to specifically isolate venous 531	
valve cells, but this has been confirmed for Efnb2 deletion in lymphatic 532	
endothelium.(72) 533	
 534	
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Detachment of VFCs from their underlying basement membrane has previously been 535	
identified in LV formation, during angiogenesis, and we now show it here in VV 536	
formation.(48, 73) Due to detachment, cell-cell contacts are highly restricted, and this 537	
is likely to impact cell-cell signalling processes.(48, 74) In vitro, soluble ephrinB2-Fc 538	
acts anti-adhesively, and the high ephrinB2 expression in VFCs could promote their 539	
detachment from the underlying basement membrane to facilitate reorientation and 540	
organization.(47)  541	
 542	
We have previously analysed VFC nuclear reorientation and elongation in 543	
wholemount confocal microscopy to characterise phenotypes at P0 / stage 1 of VV 544	
development.(11) Here, we show that VFCs not only protrude into the vessel lumen 545	
at this stage, but that this protrusion is abolished following homozygous Efnb2 546	
deletion.  We also identify that ingress of interstitial cells is already occurring at this 547	
early stage and confirm their persistence in P6 and adult murine VV, and in adult 548	
human VV. Their existence has previously been demonstrated in human, rat and 549	
rabbit VV, in contrast to LV, which lack interstitial cells.(2, 49, 54)  In lymphovenous 550	
valve development, mural cells are recruited into the valve leaflets during maturation, 551	
but the developmental origin of these cells in VVs is currently unknown.(54) The 552	
identity, origin and functions of these cells in VVs will be the subject of future studies. 553	
 554	
Our data showing that EphB4 is required for post-natal development is consistent 555	
with the phenotype resulting from Efnb2 deletion at P2 or P0.(11, 12) Almost all 556	
Prox1hi and Foxc2hi VFCs were absent at P6, in contrast to deletion of Ppp3r1 557	
(CnB1) in which a clear ring of Prox1 and Foxc2-expressing cells remains.(11) This is 558	
consistent with a requirement for EphB4 (and ephrinB2) to develop/maintain the 559	
	 23	
phenotype of free-edge cells to P6, rather than just growth of VV leaflets.(11) The 560	
failure to establish a local reduction in the density of smooth muscle cells (SMCs) 561	
around the VV at P6 after Ephb4 deletion at P0 is consistent with the endothelial 562	
VFC-to-SMC signaling that controls this reduction in SMC density around LVs.(31, 563	
75-77) 564	
Conclusions 565	
 566	
In addition to an increased risk of lymphatic-related foetal hydrops, we have shown 567	
that patients carrying heterozygous mutations in EPHB4 have very few VVs, with 568	
early onset deep venous reflux indicating that the observed venous insufficiency is 569	
due to venous valve aplasia.  By studying mice, it was demonstrated that ephrinB2 570	
and EphB4 pattern the organization of valve-forming cells at P0, and are required for 571	
cellular reorientation, elongation, protrusion and proliferation, adding to our 572	
understanding of the complex venous valve developmental programme. Postnatal 573	
deletion of Ephb4 leads to complete loss of the valve, which could explain the 574	
phenotype observed in the patients. 575	
 576	
  577	
	 24	
Methods 578	
 579	
Human VV ultrasonography 580	
The brachial, basilic, popliteal, and short saphenous veins underwent 581	
ultrasonographic evaluation in London (Phillips IU22 with L17-5MHz/L9-3MHz 582	
probes) and VV maximum leaflet measurements obtained offline (Xcelera Cath Lab 583	
software, Phillips). Reproducibility was determined previously.(11) For each vein, the 584	
number of VVs and VV length was normalised to the mean value in the respective 585	
control veins from our existing control population, and additional new controls, and 586	
the mean number of VVs per vein, per patient, was compared. Deep venous 587	
(popliteal) reflux duration was measured bilaterally after distal manual compression 588	
whilst standing, and the mean taken, with reflux defined as ≥0.5s, and severe reflux 589	
as >1s.(78-80) Because deep venous reflux is rare, popliteal venous reflux was not 590	
routinely measured in the entire control population, but was subsequently measured 591	
in additional controls.(81) Genotyping was performed at St George’s, University of 592	
London and in Bergen.(21) 593	
 594	
Mouse lines 595	
Wildtype analyses were carried out in BALB/C mice obtained from Charles River UK. 596	
Prox1CreERT2 (12), Rosa26mTmG (82), Efnb2lx (83), and Efnb2GFP (84) mice have 597	
been described previously and were maintained on C57BL/6 backgrounds. 598	
Tamoxifen/4OH-Tamoxifen (in peanut or sunflower oil, Sigma) was injected i.p. either 599	
1mg at E15 for analysis at P0, or 50µg at P0 for analysis at P6 in order to induce Cre 600	
activity in Prox1CreERT2 mice.(12) To delay labour 37.5µg/g.Ms weight progesterone 601	
was given i.p. at E15+E18 and embryos analysed at ‘E19’, equivalent to P0. We 602	
	 25	
compared VV in Prox1CreERT2+ with Prox1CreERT2- littermate controls in all deletion 603	
experiments. 604	
 605	
Electron microscopy 606	
Mice were culled and perfused via the aorta with heparinised PBS (hPBS, 25mg/L, 607	
MP Biomedicals) prior to fixation overnight in glutaraldehyde (2.5% v/v in 0.1M 608	
cacodylate buffer, pH 7.4, 4oC) and post-fixation in osmium tetroxide (1% w/v in 0.1M 609	
cacodylate, pH 7.4, 4oC) for 1.5hrs. All samples were dehydrated through graded 610	
ethanols, equilibrated with propylene oxide, infiltrated with epoxy resin (TAAB) and 611	
polymerised at 70oC for 24hrs. Semithin sections (0.45µm) were cut and stained with 612	
1% Toluidine Blue. For analysis of protruding VFCs, >90 serial semithin sections 613	
were analysed per sample (unpaired t test). For 3D reconstructions at P0, semi-thin 614	
sections (0.45µm) were photographed (Leitz DMRB microscope, Micropublisher 615	
3.3RTV camera), aligned in ImageJ (NIH) and reconstructed using Amira (Thermo 616	
Fisher Scientific). Ultrathin sections (50-70nm, Reichert-Jung ultramicrotome) were 617	
mounted and contrasted using uranyl acetate/lead citrate for examination (Hitachi 618	
H7600, 80kV, AMT digital camera).(85) For quantification of interstitial cells at P6, the 619	
length of the leaflet was measured in ImageJ, and the number of whole interstitial cell 620	
nuclei counted. Human great saphenous veins (obtained during coronary artery 621	
bypass grafting) were opened prior to processing as per murine samples, with 622	
visualisation of ultrathin sections using a Hitachi S-3500N microscope.  623	
 624	
Immunohistochemistry 625	
Mice were culled and perfusion fixed via the aorta and femoral vein by perfusion with 626	
hPBS followed by 4% formaldehyde, and then further fixed for 24hrs. The external 627	
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iliac and femoral veins were excised, embedded in wax, and 5µm sections were 628	
incubated with primary antibody and washed prior to amplification using polymer 629	
horseradish peroxidase (Menarini) and signal detection using SG peroxidase 630	
substrate (Vector).  Sections were photographed using a Micropublisher 3.3RTV 631	
camera mounted on a Leitz DMRB microscope with PL Fluotar ×20 lens (Leica).  632	
 633	
Wholemount immunostaining and analysis  634	
Mice were culled and perfused with hPBS via the aorta prior to fixation in 4% 635	
paraformaldehyde (PFA) followed by blocking in 3%v/v donkey serum, 0.3% Triton-636	
x100 and further dissection prior to incubation with primary antibodies, and washing 637	
prior to localisation with fluorophore-conjugated secondary antibodies. Samples were 638	
finally dissected and mounted in Prolong Gold (Invitrogen). Valves were imaged 639	
using a Leica SP5 confocal microscope (1024x1024 resolution, 8-bit) to produce Z 640	
projections (NIH ImageJ) of median filtered (Leica LASAF/ImageJ, except for 641	
connexin localisation or fluorescence quantification) stacks. Lookup tables were 642	
linear. Control samples were incubated either with the appropriate non-immune IgG 643	
and then secondary antibody, or streptavidin-conjugated fluorophore alone 644	
(Supplementary Figure 2A).  645	
 646	
For analysis of VFC organization, Prox1hi nuclear elongation (proportion with 647	
length:width ratio ≥2) and reorientation (proportion with long axis ≥40degrees from 648	
the vessel centreline, in nuclei with length:width ratio ≥2) were quantified in z-649	
projections (NIH ImageJ) as previously described.(11, 48) 650	
 651	
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For analysis of Efnb2GFP expression at E18-P0 (Figure 4) Z-projections of confocal z-652	
stacks were oriented with flow left to right and the centre line of the vessel horizontal. 653	
For each valve 7-12 10x100µm regions of interest, each centred on the VFC 654	
upstream edge, were analysed (ImageJ). Mean intensity profiles for each fluorophore 655	
were converted to z-scores and the mean of 6 VVs plotted. At E18, areas with and 656	
without Prox1hi organizing VFCs were analysed separately. 657	
For analysis of areas of expression of Ephb4 and Efnb2GFP at E18 (Figure 2B) an 658	
XZ projection (13.6µm deep) across the reorientating VFCs was reconstructed (NIH 659	
ImageJ) and the relative fluorescence intensity profile for Efnb2GFP and EphB4 660	
plotted. For quantification, for each valve 4-6 50µm linear regions of interest were 661	
drawn, centred on the VFC leading edge, at E18, for N=6 VVs. Ephb4 upstream vs 662	
downstream intensity was compared (T Test). 663	
 664	
For analysis of cell orientation by co-immunostaining of nucleus and Golgi, stacks of 665	
0.5µm optical sections were analysed (ImageJ) to identify the Golgi for each VFC, 666	
and an arrow drawn from nuclear centre to Golgi centre. The z-projection of all 667	
arrows is shown.  668	
 669	
Antibodies 670	
Antibodies: Rabbit anti- Cx43 (Cell Signaling Technology 3512), Cx37 (CX37A11, 671	
Alpha diagnostics), Prox1 (11-002P, Angiobio), ki67 (ab15580, Abcam), and Golgi 672	
apparatus protein 1 (ab103439, Abcam); sheep anti- Foxc2 (AF6989, R&D); goat 673	
anti- EphB4 (BAF446, R&D); rat anti- PECAM1 (clone MEC 13.3, BD); and mouse 674	
anti- α smooth muscle actin (clone 1A4 conjugated to Cy3, Sigma). For fluorescence 675	
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signal detection secondary antibodies or streptavidin were conjugated to Dylight-676	
405/488/550/649 (Jackson Immunoresearch).  677	
 678	
Statistics 679	
For VV developmental stage 0-4 quantification, data represent the proportion of VV 680	
reaching each developmental stage. P values represent the difference in proportion 681	
of valves at each stage versus their wild-type littermates (Chi square/Fisher’s Exact 682	
test as appropriate). Comparisons of VFC nuclear elongation and reorientation 683	
between groups were analysed by one-way ANOVA & Bonferroni post hoc tests. Age 684	
and sex matching for patient ultrasonography was tested respectively by two-tailed 685	
unpaired t-test and Fisher’s exact test. All analyses were carried out using IBM SPSS 686	
Statistics 24, and Graphpad PRISM v8. A P value less than 0.05 was considered 687	
significant. Ultrasonographers were blinded to participant genotype during scanning, 688	
and image analysis/quantification. Experiments were not randomised.	689	
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Figure 1 935	
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Figure 1: EPHB4 mutations cause human VV failure 938	
 939	
A) VVs (arrowheads) were readily identifiable in the veins of controls, including an 940	
unaffected relative, but were rare in patients with a mutation in EPHB4. B-mode and 941	
color doppler images are shown of the popliteal vein. Blood flow left to right, velocity 942	
indicated by color scale. Bar=2mm 943	
 944	
B) Fewer VVs per vein were seen in participants with mosaic or constitutive 945	
(heterozygous) EPHB4 mutation (P=1.7x10-11, ANOVA). N=92 veins in 13 controls, 946	
and 40 veins in 5 patients with EPHB4 mutation (mosaic or constitutive). Data points 947	
represent individual veins. Het = heterozygous. 948	
 949	
C) Popliteal (deep) venous reflux was identified in mosaic and constitutive carriers of 950	
EPHB4 mutations (P=0.036, Mann-Whitney). Blood velocity ≥0.5s indicates reflux 951	
and ≥1s indicates severe reflux (red dotted lines). Data points represent mean of left 952	
and right popliteal reflux duration for each individual. 953	
 954	
D) Representative blood velocity in the popliteal vein during reflux testing is shown 955	
for an unaffected relative (with no significant reflux, arrowheads) and a patient 956	
carrying an EPHB4 mutation, demonstrating significant deep venous reflux (dotted 957	
line = 2.14s, bar=500ms). Throughout all figures, antegrade blood flow is from left to 958	
right. Error bars indicate SEM. 959	
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Figure 2 961	
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Figure 2: Expression of EphB4 in Efnb2GFP reporter E18 and P0 964	
 965	
A) Localisation of PECAM1 (blue), Ephb4 (magenta), and Prox1 (white), Efnb2:GFP 966	
(green) in heterozygous Efnb2GFP mice at E18. Part of an E18 VV is shown, and the 967	
white boxed area (which contains organizing VFCs) is shown enlarged in single 968	
channel images. Only the anterior vein wall is shown. Arrowhead indicates a VFC 969	
nearer the inferior edge of the vessel co-expressing Ephb4 and Efnb2GFP. The 970	
schematic indicates stages 0 and 1 of VV development, as previously defined in Ref 971	
11. Red=Prox1hi VFCs, which form a continuous line across the anterior vein wall at 972	
stage 1. The orientation of all confocal z-stacks is indicated and is the same 973	
throughout all figures. wt = wildtype. 974	
B) An XZ projection (13.6µm deep), and the fluorescence intensity profile for 975	
Efnb2GFP and EphB4 is shown across the organizing VFCs, indicated by the yellow 976	
boxed area in A. The EphB4 signal is stronger upstream (to the left) of the VFCs 977	
(indicated by arrowheads, or “0” on the graph x axis), whilst the Efnb2GFP signal is 978	
stronger in VFCs and downstream. (P<0.0001, N=6 VV, T test). The multichannel 979	
image does not include Prox1.   980	
C) In wildtype VVs at P0, Prox1hi VFCs expressed EphB4, and it was particularly 981	
strongly expressed in the superior and inferior areas of the vein (arrowheads).  982	
D) Co-expression of Ephb4 and Efnb2 was confirmed in Efnb2GFP mice. 6µm z-983	
projections of the upper and lower regions of a valve are shown. Arrowheads indicate 984	
reorientated VFCs (orange). (Uncropped images are provided in Supplementary 985	
Figure 2B). Bars = 20µm 986	
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Figure 3 988	
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Figure 3: EphB4 is expressed at E18 and P0 and is required for normal VFC 991	
organization, and leaflet development to P6 992	
 993	
A-B) Homozygous deletion of Ephb4 at E15 (analysed at P0) resulted in disrupted 994	
organization of VFCs, similar to deletion of Efnb2, albeit some VVs appeared to 995	
develop normally. The number of VVs analysed for each condition is indicated above 996	
each bar in the chart. *=P0.008, Fisher’s Exact test. Bars = 20µm. Tam = Tamoxifen, 997	
SMA = smooth muscle alpha actin 998	
 999	
C) EphB4 was localised in wildtype P6 VVs and surrounding vein. The leaflet of a 1000	
stage 3 VV is indicated by arrowheads. L=valve lumen and C=the single 1001	
commissure. In adult VV, longitudinal sections were prepared, and EphB4 (dark blue 1002	
stain) was most strongly localised to the luminal surface of VV leaflets (black 1003	
arrowheads) and leaflet free edge (FE, enlarged in inset). The counterstain is 1004	
Nuclear Fast Red. Arrows indicate the orientation of the adult histological section 1005	
only (all confocal images are oriented as shown in Fig.2). 1006	
 1007	
D-E) Induction of homozygous Ephb4 deletion at P0 with Tamoxifen (analysis at P6) 1008	
resulted in entirely absent VV leaflets, and failure to remodel the surrounding SMCs 1009	
(arrowheads in upper panel), at P6. Only a few Prox1hi/Foxc2hi cells remained 1010	
(arrowhead in lower panel). ⁕ indicates a downstream tributary valve.  1011	
 1012	
E) Bar chart shows the proportion of VVs identified at each stage, with stage and 1013	
colour indicated in adjacent key, at P6 for the indicated genotypes. The number of 1014	
VVs analysed for each condition is given above each bar.  1015	
	 46	
****=P<0.00005, Chi Sq vs control, N=13 control VVs vs 10 Ephb4 deleted. Bars in 1016	
A,C,D = 20µm 1017	
 1018	
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Figure 4 1020	
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Figure 4: Formation of ephrinB2 expression boundary in VV-forming region 1023	
 1024	
A) Localisation of PECAM1 (blue), Prox1 (red) and Efnb2GFP reporter signal (green, 1025	
His-tagged and therefore nuclear) at E18 and P0 in heterozygous Efnb2GFP mice. 1026	
Wholemount preparation of the proximal femoral vein is shown. At E18 there was 1027	
partial, and variable, organization of VFCs. For example, in the superior area of the 1028	
VV-forming region but not the inferior area. Those areas with organization at E18 1029	
showed a weak Efnb2GFP expression boundary, which was clearer at P0 (white 1030	
arrowhead). Dotted lines indicate the femoral vein boundary, adjacent to the femoral 1031	
artery (FA). As expected, arterial ECs showed stronger Efnb2GFP signal. ⁕ indicates 1032	
an overlying arterial branch (cut).  1033	
 1034	
B-C) At E18, analysis of the relative fluorescence intensity across developing valves 1035	
revealed a peak in Efnb2GFP signal (green line) coincident with that of Prox1hi  (red) 1036	
VFCs in organizing areas, but not in adjacent areas that are not yet organized (blue 1037	
line). At both E18 and P0, Efnb2GFP signal is stronger downstream, and this 1038	
difference is more apparent at P0. Mean of 6 VVs and 7-12 regions analysed per VV 1039	
and representative regions analysed are shown boxed  (green, blue) in A. P values in 1040	
B,C are T tests comparing Efnb2GFP proximal and distal to the VFC leading edge. 1041	
NS = not significant. 1042	
D) TEM analysis at P0 showed rotated VFCs detached from underlying basement 1043	
membrane (arrowheads). Interstitial cells (⁕) populated the developing leaflet core, 1044	
and persisted at P6 and in adults. TEM micrographs are orientated at 90o to confocal 1045	
images, as indicated by arrows at P0 in D. Further examples of interstitial cells (in 1046	
murine and human VVs) are shown in Supplementary Figure 3. 1047	
	 49	
N≥6 VV and blood flow left to right at all time points and in B,C. Bar = 20µm in A; and 1048	
in D Bar = 2µm at P0-P6, 500nm in Adult. 1049	
 1050	
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Figure 5 1052	
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Figure 5: Effect of Efnb2 deletion on organization of VFCs 1055	
 1056	
A,B) Localisation of PECAM1 (blue), Prox1 (red) and SMA (white) in littermate 1057	
controls, heterozygous (Efnb2lx/wt) and homozygous (Efnb2lx/lx) mice at P0, 1058	
following Tamoxifen induction of Efnb2 deletion at E15. In controls and Efnb2lx/wt 1059	
mice valves reached stage 1 of development, as normal. Homozygous deletion 1060	
resulted in a failure to organize normally, with Prox1hi cells distributed over a wider 1061	
upstream-downstream area of the vein, and failure of VFCs to elongate and 1062	
reorientate.  1063	
B) The bar chart shows the proportion of VVs identified at stage 0 (white) and stage 1 1064	
(grey) at P0 for the indicated genotypes, and the number of VVs analysed for each 1065	
condition is given above each bar. P values derive from two-sided Fisher’s Exact test 1066	
vs control. 1067	
C) Hex-binned scatterplot of VFC elongation (length/width ratio) across the vein from 1068	
superior to inferior. N=2517 cells, ≥6 VVs.   1069	
D) Bar chart (±sem) summarising the results from (C) showing that both 1070	
heterozygous and homozygous deletion resulted in significant reductions in VFC 1071	
elongation. ANOVA with Bonferroni post hoc. For between groups ANOVA, F=109 1072	
with 2df, P=3.2x10-46. 1073	
E) Hex-binned scatterplot of VFC reorientation (in VFCs with nuclear length:width 1074	
ratio ≥2) across the vein from superior to inferior. N=1226 cells, ≥6 VVs. After 1075	
homozygous deletion, the VFCs with correctly reorientated nuclei were lost, 1076	
particularly in the centre of the vessel.  1077	
F) Bar chart (±sem) summarising the results from (E). Homozygous deletion resulted 1078	
in significantly reduced reorientation. ANOVA with Bonferroni post hoc. For ANOVA, 1079	
	 52	
F=7.1 with 2df, P=0.0009. *=P<0.05, **=P<0.005, ***P<0.0005, ****=P<0.00005. 1080	
Bars = 20µm 1081	
 1082	
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Figure 6 1084	
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Figure 6: Failure of VFCs to project into vessel lumen and abnormal integrin 1087	
expression 1088	
 1089	
A) Semi-thin longitudinal sections of P0 femoral veins showed protruding VFCs in 1090	
littermate controls, but no protruding cells were seen after homozygous Efnb2 1091	
deletion. 3D reconstructions of semi-thin sections show protruding VFCs 1092	
(arrowheads) in controls only. The schematic indicates the orientation of the semi-1093	
thin sections.  1094	
 1095	
B) A significant reduction in the mean number of sections showing protruding cells 1096	
was identified. (≥60 sections were analysed per sample, T test, N=3 VV per group, 1097	
error bars indicate SEM). 1098	
 1099	
C) Integrinα9 was expressed in a ring around the organized VFCs in littermate 1100	
controls (white arrowheads), but after homozygous Efnb2 deletion, the localisation of 1101	
integrinα9 expression was disrupted and chaotic (P<0.05, Chi Square test of the 1102	
proportion of VVs showing normal vs disrupted integrinα9 expression pattern, N≥6 1103	
VV per group) 1104	
 1105	
D) VFC polarity (indicated by white arrows) was examined by co-staining for Prox1 1106	
(magenta), PECAM1 (blue) and Golgi (green). Polarity was determined for individual 1107	
VFCs using 0.5µm sections, and a z-projection of 2-4 confocal sections shown on the 1108	
right (area enlarged outlined by dotted box,). In littermate controls, cells in the central 1109	
region of the vein were aligned with the line of organized VFCs, whilst after 1110	
homozygous Efnb2 deletion, cell alignment was chaotic. P<0.05, Chi Square test of 1111	
	 55	
the proportion of VVs showing normal vs chaotic VFC alignment, N≥8 VV per group. 1112	
Yellow arrows indicate VFCs on the posterior vein wall. Bars in A,C,D 20µm. C and D 1113	
are oriented as shown in Fig.2A. 1114	
 1115	
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Figure 7 1117	
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Figure 7: Efnb2 deletion disrupts gap junction protein expression pattern, and 1120	
proliferation 1121	
 1122	
A) Localisation of PECAM1 (blue), and either Cx37 or Cx43, as indicated (magenta) 1123	
around VFCs at P0 in heterozygous Efnb2GFP (green) mice. As expected, at P0 1124	
Cx37 was localised to Efnb2GFP-expressing VFCs, primarily forming large gap 1125	
junction plaques (examples indicated between arrowheads) and Cx43 was localised 1126	
to endothelium upstream of these VFCs (region to the left of the arrowheads). 1127	
Smaller plaques are also identifiable. 1128	
 1129	
B) Localisation of PECAM1 (blue), Prox1 (red) and either Cx37 or Cx43, as indicated 1130	
(green), after homozygous deletion of Efnb2. The tightly regulated expression pattern 1131	
of Cx37 was disrupted, with expression over a wider area (arrowheads) and the 1132	
typical appearance of larger plaques was lost. The expression pattern of Cx43 was 1133	
also disrupted and no longer confined to upstream of VFCs (arrowheads). (P<0.05, 1134	
Chi Square test of the proportion of VVs showing normal (confined) vs disrupted 1135	
expression pattern, N≥6 VV per group). 1136	
C-D) The proportion of proliferating VFCs was assessed by colocalisation of Prox1 1137	
and Ki67 (arrowheads). Ki67+ve VFCs were easily identified in littermate controls, 1138	
but far fewer proliferating VFCs were identifiable after homozygous Efnb2 deletion. 1139	
The inferior region of the vein is shown. (P<0.00005, unpaired T test, N≥6 VV per 1140	
group, error bars indicate SEM). Bars in A-C = 20µm 1141	
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